JanSvenda

Hello fellow CoBFers, I hope you are all doing well in these turbulent times! For those of you who are still scouring the OTC market looking for the oddball deep value play, I and couple of other OTC guys have prepared something you will want to check out. We have created a digital version of Walker’s Manual. We build an online database of over 400 meaningful OTC stocks. Therefore, it includes most of the companies OTC investors should be aware of. Our database includes our own comments about each of the stocks, links to any relevant sources, and fundamental data points through which you can filter the database. It also features a comment section where users can share their view on individual stocks. We have a formidable number of dark stocks for which we provide financials. Say goodbye to the clunky and inefficient screener on OTCmarkets.com or time-consuming A to Z search. Check out an intro video to our database - You can get your instant access here - https://svendamanual.com/product/one-year-subscription-to-database/ If you buy our annual subscription to the database, you will be getting a database which will be updated and to which we will be adding new stocks, features alongside new fundamental data points. We also frequently write research and with the annual subscription you will get 50% off of any new research we put up. I wish you successful hunting in the OTC world, Jan

Dear fellow CoBFers who invest in OTC, As you might remember from 2017 to 2019 I used to run a newsletter focused on the OTC market. During that time, I scoured the notoriously inefficient market for companies that are meaningful and exhibit an investment opportunity. No frauds, no pump and dumps. Only companies that are of interest to the serious enterprising investor. I like to think that I looked at every company in the OTC market at least twice. I went the A to Z route a couple of times, I maintained many simple screeners, I tracked Form 25s, 15s and much more. Given the sheer size of the market, one can’t be completely sure of his/her coverage of the market, but I believe my reach is formidable. In late 2018 I decided to compile all of the past research tied to the newsletter and offer it to investors. Just in case you missed it, I am now offering an updated and discounted version of my Svenda’s Manual. What I have added are the reports from 2019 which have coverage of over 100 stocks over 80 pages. Adding further reference points for your own OTC research. I have also added a folder filled with financials tied to 36 dark stocks. Thus, you will be able to also expand your financials database. You can find samples of the manual here - https://jansvenda.com/sample/ As I like to say, simply knowing about an OTC company will make sure you are halfway in discovering an investment opportunity. These documents will allow you to achieve that and greatly reduce the risk of you missing out on the next OTC opportunity. I believe it will be especially useful when the next crisis comes around. You can buy the document through this PayPal link - https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=C3QJ2UHTJBT9E Once you purchase, you will receive the full PDF documents straightaway. Join the ranks for already content owners of the manual such as Andrew Kuhn of Focused Compounding - https://twitter.com/FocusedCompound/status/1230584850794655745, David Flood of Elementary Value - https://www.elementaryvalue.com/blog/svendas-manual-of-otc-stocks-updated-and-now-on-sale-for-149 and others. I will greatly appreciate any feedback. Thanks, Jan Financial Disclosure: I may own shares in the companies listed in the manual. Trading in OTC shares carries specific risks that one needs to understand before initiating a position. Due diligence is essential.

From my amateur knowledge, I believe child mortality is the major change here. Thus people living to their 90s are certainly many more, but the difference might not be that staggering. My post is predominantly about people living longer than 100 years etc. Just a random tidbit of info from wiki; Having survived until the age of 21, a male member of the English aristocracy in this period could expect to live:[27] 1200–1300: to age 64 1300–1400: to age 45 (because of the bubonic plague) 1400–1500: to age 69 1500–1550: to age 71 Interestingly enough men from Glasgow, for example, have a similar life expectancy to that of the English aristocracy in the 16th century - https://en.wikipedia.org/wiki/Glasgow_effect

Hoping for a cure to aging (or a substantially longer life span) is a double-edged sword in my mind. Sure, people that are self-aware and are able to reflect upon their actions and that of others will be a benefit to the society. On the other hand, people that are complete opposites will live to spread their misconceptions long after society would be without this burden. I am ambiguous about living longer. Death is so far the only other sure natural catalyst for change apart from technology.

Hey, reviving this topic from the dead with my SA article - https://seekingalpha.com/article/4237147-mills-music-trust-strong-dividend-yielder-continues-perform The trust is still solid and the yield is meaningful.

Hey, As some of you may know in the past 15 months I ran a newsletter exclusively focused on the OTC space. Recently, I decided to compile all of the past research tied to the newsletter and offer it to investors. I am offering two versions of my ‘Svenda’s Manual of OTC Stocks’. Abridged Version This will give you access to 56 long ideas spanning 348 pages. On top of the 56 ideas, you will also get access to a report where I build a portfolio of 20 interesting community banks. This version is priced at $199. You can find a sample of the document attached to this message. Full Version This will get you everything in the abridged version and you will also acquire a serious coverage of 351 meaningful stocks in the OTC land over 402 pages. Out of those 351 stocks, 25 are dark where I share information that can be hard to get. This version is priced at $399. You can find a sample of the document attached to this message. The best way to purchase the manual is now through David J. Flood's blog Elementary Value. He also shares his experience with the full version of the manual - https://www.elementaryvalue.com/investing-blog/svendas-manual-of-otc-stocks-my-readers-can-get-it-at-a-discount Now, you might be wondering; ‘Are there any investment opportunities?’ Most certainly. 32 stocks out of the 56 long ideas still have not moved by more than 20% (up or down). The community bank portfolio is up only 4.85% so far. The latest report is from early October. Thus, the research is relevant and up to date. The performance and volume analysis of the long ideas - https://seekingalpha.com/article/4219541-otc-performance, also shows that the ideas are actionable for various portfolio sizes. The second question that might pop in your head could be; ‘Okay, what is the use of the other research?’ It is a powerful reference point that you can use when doing your own research. Many OTC stocks have sparse public ‘coverage’. There might be some analysis from someone that is five years old. There might not be anything out there as is often the case. Given the sheer amount of meaningful OTC stocks I researched, you are going to acquire a unique source of relevant information. As I like to say, simply knowing about an OTC company will make sure you are halfway in discovering an investment opportunity. These documents will allow you to achieve that and greatly reduce the risk of you missing out on the next OTC opportunity. I will greatly appreciate any feedback. Thanks, Jan Svendas_Manual_Of_OTC_Stocks_-_Abridged_Sample_.pdf Svendas_Manual_of_OTC_Stocks_-_Sample.pdf

I would recommend Ed Thorp's 'Beat The Market'. It really drills down the need for an 'edge' which I feel sometimes value investors easily forget (as they go on to search for that 'compounder'). He even ends up talking about demutualized community banks (a fundamental value play) after his arb career.

First of all, I would like to thank everyone for their input much appreciated. Yeah, redeveloping makes more sense. I will see what I can do here in Europe where regulation is going to be a challenge to overcome. Thanks for the links Cigarbutt and the other suggestions, they are useful. From a quick scan, Baltic looks cheap, Scandi looks good as well compared to Czech prices. Anyway, I might update this thread once I will actually move on and buy smth.

Hey Nate, thanks for the detailed reply. Did you read anything before you started? Sure I just started to look at online listings to get a sense of the stuff, but the more hands-on the better I suppose. Nice way of redeveloping. What was your biggest challenge in this plan? Also have you encountered any natural problems (damage by animals or certain plans) with your timberland? Was theft any issue at all? Also, have you thought about leveraging the asset (get a loan after purchase with collateral being the asset)? I live in the Czech Republic in Europe (i just use swiss hosted email), so I would be buying around the area instead of the US. I would be up for buying somewhere further east, but only after the first purchase.

Yeah, I view this as an investment (long-term appreciation & diversification). I am not a huge fan of gold (physical).

Haha yeah, did not want to read the pitch for the tenth time. Although I hope that value is going to be created after the reshuffling. Thanks for the note. I am fine with taking the time to learn as much as possible. I also understand that the purchase is really only the start as the maintenance is crucial. I will be buying in Europe so some factors might be slightly different.

Hey, I am wondering if there are people here that own timberland. I am not talking about stocks like KEWL etc., I mean physical ownership. If so, would you be able to share some sources on how you prepared for your first purchase and generally share some timber-related sources? One of my long-term goals is to continuously accumulate ownership of this asset class. In my mind timberland should also present an easier way to acquire solid collateral than say buying a house etc. Thanks, Jan

Penntrade for the grey- http://www.nonamestocks.com/2017/05/ive-moved-to-penntrade.html

https://www.theatlantic.com/technology/archive/2012/05/how-the-professor-who-fooled-wikipedia-got-caught-by-reddit/257134/ Here is a similar story.

Fellow sinking 'shareholder' here. I would note that the US Agency NOAA is likely the biggest issue here now. I believed that in the worst case they can sell the French part (which should on its own fetch a nice value because of the hot auction market). The NOAA apparently believes that the whole set should be kept as one and would contest the sale (as per both plans of unsecured and insiders). This certainly complicates things and the troubles with the auction become more understandable. I am not sure about the strength of NOAA's point of view, but if litigation was to really ensue, the buyer would have to be comfortable with it. We will see if a more rigorous bidding starts (and if the initial bids were just low-balling it), but I am not too sure about it. I see no appeal in taking the artifacts and setting up an exhibition out of them (apart from doing 'public good' which is why the unsecured are probably favourites here). The cash flow is unlikely to be attractive to command a high price (certainly nowhere near $200 million+). I thought that this would be offset by the French part which would put a sort of downside risk protection. Now that this is not the case, I believe zero should be regard as a clear possibility. My main learning point from PRXIQ is likely the following; When scrutinizing a legal play, map out all possible players and understand their incentive. I missed NOAA and did not pay too much attention to it because of the French rulings.